<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene E484K;N501Y;D614G literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.E484K;N501Y;D614G</span> literature reference collection</h1>
<div class="effect_section"><h2 id="syncytium_formation">Syncytium formation</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> ~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.<br/> (<a href="https://doi.org/10.3390/v13040633" class="lit_link">Kim et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="trafficking">Trafficking</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> ~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).<br/> [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied] (<a href="https://doi.org/10.3390/v13040633" class="lit_link">Kim et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.<br/> (<a href="https://doi.org/10.3390/v13040633" class="lit_link">Kim et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> ~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).<br/> (<a href="https://doi.org/10.1016/j.chom.2021.03.008" class="lit_link">Kuzmina et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_neutralization_efficacy">Vaccine neutralization efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose; n = 5) or two doses (9â€“11 days post-second dose;  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).<br/> (<a href="https://doi.org/10.1016/j.chom.2021.03.008" class="lit_link">Kuzmina et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
